||CTS: Aims and Scope
Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. CTS also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. CTS welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.
Topics of interest include:
CTS will capitalize on, and extend the reach of, the flagship journal, Clinical Pharmacology & Therapeutics (CPT), which emphasizes the clinical aspects of the pharmacological sciences, and CPT: Pharmacometrics & Systems Pharmacology, which emphasizes advances in quantitative (e.g., modeling and simulation) methods. CTS has an Impact Factor of 2.11, and is indexed in PubMed.
- Translational medicine, including studies focused on Interrogation/evaluation of mechanism-of-action, human physiology, and interruption of disease pathophysiology
- Hypothesis generating non-clinical and clinical studies, including small clinical trials
- Clinical pharmacology studies with a focus on translational research in discovery, development, regulation and use of pharmacologic agents to improve clinical outcome, and inform optimal use of therapeutics in patients
- Evaluation of various biomarkers as well as assessing the linkage between biomarker response and clinical endpoints in patients, including studies that identify or support biomarkers that can be used at any stage of drug development
- Studies of response to a therapeutic intervention in a particular disease that may translate to a response in another disease, as well as translation of safety signals across species and/or patient populations
- The science and practice of translational medicine, including topics such as models of human disease and their therapeutic implications as well as practical aspects like improvements to study design or conduct and translational medicine methods.
- Studies that guide Phase 2 dose selection
- Studies that demonstrate effective translation between basic and clinical science
- Precision medicine
- Genomic medicine, including pharmacogenomics, next generation sequencing, pharmacometabolomics, and functional genomics
- Electronic and mobile health applications as well as wearables
- Regulatory and public health policy implications of translational studies
- Quantitative and systems pharmacology, PK/PD model-based and mechanistic understanding of disease biology and pharmacology, as these relate to translational medicine
We encourage you to support CTS by submitting a paper or becoming a reviewer for the journal.
Submit your research for publication in CTS.
Title: Driving Patient-Centered Translational Medicine
Presenters: Christopher P. Austin, MD, National Institutes of Health and Sharon F. Terry, Genetic Alliance
Moderators: John A. Wagner, MD, PhD, CTS Editor-in-Chief, Takeda Pharmaceuticals International
The webinar recording is available below. You may also access the video here.
Questions about CTS can be directed to Elise Laffman-Johnson at email@example.com.